TG Therapeutics Reports $616 Million Revenue for FY 2025, Shares Surge 11.6%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 14 2026
0mins
Source: Benzinga
- Strong Financial Performance: TG Therapeutics reported preliminary total global revenue of approximately $616 million for FY 2025, with Q4 U.S. net product revenue for BRIUMVI at about $182 million, indicating robust market performance that is expected to boost shareholder confidence.
- Significant Stock Surge: Following the earnings report, TG Therapeutics shares jumped 11.6% to $31.10 on Wednesday, reflecting investor optimism about the company's growth potential, which may attract more capital inflow.
- Positive Market Reaction: Despite a broader market decline with the Nasdaq Composite falling over 200 points, TG Therapeutics' strong financial data allowed it to stand out among numerous stocks, showcasing its competitiveness in the biopharmaceutical sector.
- Optimistic Future Outlook: Although the financial figures are unaudited, the preliminary results suggest that the company is poised for continued growth, particularly in the marketing of its BRIUMVI product, which could further enhance its market share.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TGTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TGTX
Wall Street analysts forecast TGTX stock price to fall
4 Analyst Rating
3 Buy
0 Hold
1 Sell
Moderate Buy
Current: 55.830
Low
15.00
Averages
43.50
High
60.00
Current: 55.830
Low
15.00
Averages
43.50
High
60.00
About TGTX
TG Therapeutics, Inc. is a fully integrated, commercial stage biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its products include Ublituximab IV (anti-CD20 mAb), Ublituximab IV Simplified Dosing Schedule, Ublituximab Subcutaneous (anti-CD20 mAb), and Azer-cel. It is engaged in late-stage clinical development of BRIUMVI. BRIUMVI is an anti-CD20 monoclonal antibody that can be administered to adults with relapsing forms of multiple sclerosis (RMS) in a one-hour infusion every 24 weeks, following the starting dose. It is used for treatment of adults with clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The Company is also engaged in ULTIMATE I & II Trials Evaluating Single Agent Ublituximab in RMS. Its ENHANCE Phase 3b Trial is an ongoing, multi-center, open-label study designed to evaluate alternative dosing regimens for BRIUMVI in patients with RMS.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analysis of XBI ETF Trading Dynamics
- 52-Week Price Range: The XBI ETF has a 52-week low of $82.04 and a high of $150.49, with the latest trade at $149.87, indicating strong investor interest and volatility near its peak, reflecting ongoing confidence in the biotech sector.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average allows investors to better assess XBI's price trends, enabling more precise investment strategies and enhancing the effectiveness of trading decisions.
- ETF Unit Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units', providing flexibility that allows ETFs to better accommodate market demand, thus increasing their attractiveness as investment vehicles.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify significant inflows or outflows; inflows necessitate purchasing underlying assets, while outflows may lead to selling, impacting the performance of individual stocks within the ETF.
See More
Quantum BioPharma Advances Novel MS Drug Candidate Lucid-MS
- Drug Development Progress: Quantum BioPharma is advancing Lucid-MS, a novel drug candidate targeting multiple sclerosis by directly protecting the myelin sheath, with plans to enter phase 2 clinical trials that could transform current treatment paradigms.
- Significant Market Demand: The global market for MS therapeutics is projected to reach $27.4 billion in 2024 and grow to $38.62 billion by 2030, highlighting the urgent need for effective treatments, with Quantum BioPharma's innovative drug poised to address this gap.
- Successful Clinical Trials: The phase 1 clinical trial for Lucid-MS has been successfully completed, demonstrating a favorable safety profile and good tolerability, laying the groundwork for subsequent patient trials that could offer unprecedented potential for restoring lost functions.
- Collaborative Research Prospects: Quantum BioPharma is collaborating with Massachusetts General Hospital to utilize advanced imaging techniques to assess Lucid-MS's effectiveness, which could provide direct evidence of the drug's clinical impact and further accelerate its path to market.
See More
Quantum BioPharma Advances Novel MS Drug Candidate Lucid-MS into Phase 2 Trials
- Drug Development Progress: Quantum BioPharma's Lucid-MS is advancing into Phase 2 clinical trials, aiming to directly target the myelin sheath in multiple sclerosis (MS) patients, potentially filling a significant gap in current treatments and improving patient quality of life.
- Significant Market Potential: The global market for MS therapeutics was valued at approximately $27.4 billion in 2024 and is projected to reach $38.62 billion by 2030, highlighting the urgent need for effective therapies, with Quantum BioPharma's innovative drug poised to capture a substantial share.
- Successful Clinical Trials: Lucid-MS demonstrated a favorable safety and tolerability profile in Phase 1 trials, successfully completing dosing among healthy volunteers, laying the groundwork for subsequent patient trials, and offering new hope for MS patients if results are positive.
- Strong Scientific Team: Quantum BioPharma boasts a top-tier scientific team, including experts with extensive experience in medicinal chemistry and neurology, ensuring a rigorous development process for Lucid-MS, which aims to be the first treatment to directly protect the myelin sheath.
See More
TG Therapeutics Reports Positive Results for Subcutaneous BRIUMVI
- Positive Clinical Results: TG Therapeutics reported that in a small study involving 11 patients with myasthenia gravis, most experienced significant improvements in daily symptoms after six months of treatment with the new subcutaneous BRIUMVI, indicating its efficacy and safety profile.
- Sales Forecast Increase: The company reported approximately $205 million in global revenue for Q1 2026 and raised its full-year sales forecast to about $925 million, reflecting strong market performance and growth potential for BRIUMVI.
- Investor Sentiment Shift: Despite a 2% increase in TG Therapeutics' stock price on Wednesday, retail sentiment shifted from 'extremely bullish' to 'bullish', indicating cautious optimism among investors regarding future catalysts and stock price movements.
- Analyst Ratings Optimistic: Among the nine analysts covering TGTX, seven rated it 'Buy' or higher, with a 12-month average price target of $48, demonstrating confidence in the company's future growth prospects.
See More
Trump's New Attacks on Iran Drive Oil Prices Up
- Oil Price Surge: Trump's new attacks on Iran have led to a rise in oil prices, heightening market tensions regarding the Middle East situation, which could destabilize future supply chains and impact the global economy.
- Futures Market Stability: While futures markets remained relatively unchanged, the increase in oil prices may raise investor concerns about inflation, potentially affecting stock market performance, particularly in energy-related stocks.
- Oracle Earnings Decline: Oracle's stock plummeted following disappointing earnings, reflecting market concerns about its future growth prospects, which may lead investors to reassess its position in the tech industry.
- SpaceX IPO Anticipation: The upcoming SpaceX IPO is generating significant market interest regarding its potential valuation and future growth, likely attracting a wave of investor attention and further fueling investment enthusiasm in the aerospace sector.
See More
Stock Market Volatility Driven by AI Fears and Trump's Iran Threats
- Market Volatility Drivers: The stock market experienced significant fluctuations on Tuesday, primarily due to heightened investor fears regarding artificial intelligence and threats from Trump concerning Iran, which led to a sharp decline in indices.
- Investor Sentiment Impact: The uncertainty surrounding future economic conditions has dampened investor sentiment, resulting in a rebound from lows but an overall weak trend, indicating a lack of confidence in economic recovery.
- Inflation Data Focus: The market is anticipating the upcoming Consumer Price Index (CPI) data release, with analysts widely expecting inflation to continue influencing monetary policy, potentially leading the Federal Reserve to adopt a more cautious stance.
- Future Outlook: Amid rapid advancements in AI technology, the market is filled with concerns regarding the prospects of related companies, prompting investors to closely monitor policy changes and global economic dynamics to adjust their investment strategies.
See More
Analysis of XBI ETF Trading Dynamics
- 52-Week Price Range: The XBI ETF has a 52-week low of $82.04 and a high of $150.49, with the latest trade at $149.87, indicating strong investor interest and volatility near its peak, reflecting ongoing confidence in the biotech sector.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average allows investors to better assess XBI's price trends, enabling more precise investment strategies and enhancing the effectiveness of trading decisions.
- ETF Unit Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units', providing flexibility that allows ETFs to better accommodate market demand, thus increasing their attractiveness as investment vehicles.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify significant inflows or outflows; inflows necessitate purchasing underlying assets, while outflows may lead to selling, impacting the performance of individual stocks within the ETF.
See More
Quantum BioPharma Advances Novel MS Drug Candidate Lucid-MS
- Drug Development Progress: Quantum BioPharma is advancing Lucid-MS, a novel drug candidate targeting multiple sclerosis by directly protecting the myelin sheath, with plans to enter phase 2 clinical trials that could transform current treatment paradigms.
- Significant Market Demand: The global market for MS therapeutics is projected to reach $27.4 billion in 2024 and grow to $38.62 billion by 2030, highlighting the urgent need for effective treatments, with Quantum BioPharma's innovative drug poised to address this gap.
- Successful Clinical Trials: The phase 1 clinical trial for Lucid-MS has been successfully completed, demonstrating a favorable safety profile and good tolerability, laying the groundwork for subsequent patient trials that could offer unprecedented potential for restoring lost functions.
- Collaborative Research Prospects: Quantum BioPharma is collaborating with Massachusetts General Hospital to utilize advanced imaging techniques to assess Lucid-MS's effectiveness, which could provide direct evidence of the drug's clinical impact and further accelerate its path to market.
See More
Quantum BioPharma Advances Novel MS Drug Candidate Lucid-MS into Phase 2 Trials
- Drug Development Progress: Quantum BioPharma's Lucid-MS is advancing into Phase 2 clinical trials, aiming to directly target the myelin sheath in multiple sclerosis (MS) patients, potentially filling a significant gap in current treatments and improving patient quality of life.
- Significant Market Potential: The global market for MS therapeutics was valued at approximately $27.4 billion in 2024 and is projected to reach $38.62 billion by 2030, highlighting the urgent need for effective therapies, with Quantum BioPharma's innovative drug poised to capture a substantial share.
- Successful Clinical Trials: Lucid-MS demonstrated a favorable safety and tolerability profile in Phase 1 trials, successfully completing dosing among healthy volunteers, laying the groundwork for subsequent patient trials, and offering new hope for MS patients if results are positive.
- Strong Scientific Team: Quantum BioPharma boasts a top-tier scientific team, including experts with extensive experience in medicinal chemistry and neurology, ensuring a rigorous development process for Lucid-MS, which aims to be the first treatment to directly protect the myelin sheath.
See More
TG Therapeutics Reports Positive Results for Subcutaneous BRIUMVI
- Positive Clinical Results: TG Therapeutics reported that in a small study involving 11 patients with myasthenia gravis, most experienced significant improvements in daily symptoms after six months of treatment with the new subcutaneous BRIUMVI, indicating its efficacy and safety profile.
- Sales Forecast Increase: The company reported approximately $205 million in global revenue for Q1 2026 and raised its full-year sales forecast to about $925 million, reflecting strong market performance and growth potential for BRIUMVI.
- Investor Sentiment Shift: Despite a 2% increase in TG Therapeutics' stock price on Wednesday, retail sentiment shifted from 'extremely bullish' to 'bullish', indicating cautious optimism among investors regarding future catalysts and stock price movements.
- Analyst Ratings Optimistic: Among the nine analysts covering TGTX, seven rated it 'Buy' or higher, with a 12-month average price target of $48, demonstrating confidence in the company's future growth prospects.
See More
Trump's New Attacks on Iran Drive Oil Prices Up
- Oil Price Surge: Trump's new attacks on Iran have led to a rise in oil prices, heightening market tensions regarding the Middle East situation, which could destabilize future supply chains and impact the global economy.
- Futures Market Stability: While futures markets remained relatively unchanged, the increase in oil prices may raise investor concerns about inflation, potentially affecting stock market performance, particularly in energy-related stocks.
- Oracle Earnings Decline: Oracle's stock plummeted following disappointing earnings, reflecting market concerns about its future growth prospects, which may lead investors to reassess its position in the tech industry.
- SpaceX IPO Anticipation: The upcoming SpaceX IPO is generating significant market interest regarding its potential valuation and future growth, likely attracting a wave of investor attention and further fueling investment enthusiasm in the aerospace sector.
See More
Stock Market Volatility Driven by AI Fears and Trump's Iran Threats
- Market Volatility Drivers: The stock market experienced significant fluctuations on Tuesday, primarily due to heightened investor fears regarding artificial intelligence and threats from Trump concerning Iran, which led to a sharp decline in indices.
- Investor Sentiment Impact: The uncertainty surrounding future economic conditions has dampened investor sentiment, resulting in a rebound from lows but an overall weak trend, indicating a lack of confidence in economic recovery.
- Inflation Data Focus: The market is anticipating the upcoming Consumer Price Index (CPI) data release, with analysts widely expecting inflation to continue influencing monetary policy, potentially leading the Federal Reserve to adopt a more cautious stance.
- Future Outlook: Amid rapid advancements in AI technology, the market is filled with concerns regarding the prospects of related companies, prompting investors to closely monitor policy changes and global economic dynamics to adjust their investment strategies.
See More
